What are the risk-factors with an impact on fatality rate in fulminant hepatitis A?

Similar documents
Natural History of Chronic Hepatitis B

Current Concepts in Diagnosis and Management of Acute Liver Failure

Chronic Hepatitis B: management update.

Acute hepatitis A to E, diagnosis and management

Natural History of HBV Infection

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Should we treat hepatitis B positive pregnant women to prevent mother to child transmission?

Viral hepatitis and Hepatocellular Carcinoma

Viral Hepatitis Diagnosis and Management

Chronic hepatitis B virus (HBV) infection remains a major

Does Viral Cure Prevent HCC Development

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Diagnosis of Acute HCV Infection

Therapies for DILI: NAC, Steroids or NRF-2 activators?

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Hepatitis and pregnancy

La riattivazione dell epatite virale nel paziente in terapia biologica

NATURAL HISTORY OF HEPATITIS B

Worldwide Causes of HCC

Professor Vincent Soriano

The Alphabet Soup of Viral Hepatitis Testing

Healthy Liver Cirrhosis

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Management of Chronic Hepatitis B in Asian Americans

Hepatitis E Virus Infection. Disclosures

Diagnostic Methods of HBV and HDV infections

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

An Update HBV Treatment

Epidemiological profiles of viral hepatitis in Italy Effects of migration

29th Viral Hepatitis Prevention Board Meeting

Management of Decompensated Chronic Hepatitis B

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

White Nights of Hepatology 2016

Hepatitis C. Core slides

Update of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital

Viral Hepatitis And Liver Transplantation

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

VIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms

NH2 N N N O N O O P O O O O O

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Over the past 20 years, the Centers for Disease. Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes

Fulminant Hepatic Failure: Clinical Spectrum & Outcome

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

Test Name Results Units Bio. Ref. Interval

Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018

Worldwide Causes of HCC

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

HIV Basics: Clinical Tests and Guidelines

Acute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Vaccination of patients with chronic viral hepatitis against Hepatitis A and Hepatitis B

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

HBV Therapy in Special Populations: Liver Cirrhosis

Hepatitis delta: often forgotten?

Test Name Results Units Bio. Ref. Interval

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )

Occult Hepatitis B Infection: why, who and what to do?

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Il trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici

Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta

SIRS Score Reflects Clinical Features of Non-Acetaminophen-Related Acute Liver Failure with Hepatic Coma

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual

Hepatitis D. Challenges in 2018

I wish that I had some conflicts to declare

What have we learned from HBV clinical cohorts?

Hepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C

Update on HIV-HCV Epidemiology and Natural History

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

Perinatal Transmission of Hepatitis C Virus

Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus

HAV HBV HCV HDV HEV HGV

What factors determine the severity of hepatitis A-related acute liver failure?

HBV Diagnosis and Treatment

MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections

Recent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance

Tenofovir as a drug of choice for the chronic hepatitis B treatment

Spontaneous hepatitis B e antigen (HBeAg) seroconversion

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Management of Acute HCV Infection

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Cornerstones of Hepatitis B: Past, Present and Future

Chronic infection with hepatitis B virus (HBV) is still a

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco

Treatment of chronic hepatitis delta Case report

coinfected patients predicts HBsAg clearance during long term exposure to tenofovir

Transcription:

What are the risk-factors with an impact on fatality rate in fulminant hepatitis A? Daniel Shouval Liver Unit Hadassah-Hebrew University Jerusalem, Israel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Hepatitis in Chimpanzees inoculated with HAV???? *Adopted from Nainan et al.clinical Microbiology Reviews 2006;19;:63

Cumulative Experience Acute HAV infection resolves spontaneously in > 99% of infected individuals Fulminant hepatitis is rare with a wide range of estimated rates, up to 1:10,000 or more in immuno-competent individuals Patients with chronic liver disease are at an increased risk for developing severe or fulminant hepatitis Mortality in fulminant hepatitis is rare and linked to hepatitis A in older age > 50 y

Patients Survival in Fulminant Viral Hepatitis Without OLT* Etiology Survival Hepatitis A 66% Paracetamol 50% Hepatitis B 39% Hepatitis C 20% Halothane 13% *O Grady et al, Gastroenterology 1988; 94: 1186.

Source: US Viral Hepatitis Surveillance Program, 1983-1989 Similar data CDC Hepatitis surveillance report No 58,2003 p 1 Age-specific Mortality Due to Hepatitis A Age group (years) Case-Fatality (per 1000) <5 3.0 5-14 1.6 15-29 1.6 30-49 3.8 >49 17.5 Total 4.1

Fulminant Hepatitis A in children Number of reports is rising? Turkey 4 cases (6/04-11/06) UK 9 cases (1991-2000)) Argentina 128 cases (5/82-9/02) Argentina 41 cases (9/03-1/06) Brazil 13 cases (1998-2007) Reports are retrospective and released by individual centers J Viral Hepatitis 2008;15:S66; J Ped Gastroenterol & Nutr 2005;40:575; Pediat Crit Care Med 2002;3:227; Liver Int 2007;Arch Dis Child 2008;93:48

Rising Incidence of Fulminant Hepatitis A irrespective of age* Year 2003 2004 2005 2006 2007 2008 % 0 3.4 3.2 6.0 7.7 13.0 35/568 HAV patients had fulminant hepatitis (KCH) Spontaneous survival 20/35 (57.1%) Transplanted 13/35 (37.1%) Died 5/35 (14.3%) Total survival 85.7% *Kim JM et al. Korean J Hepatol 2008;14:474

Etiology of Acute Liver Failure in Adults Acetaminophen Drugs HBV HAV 7% 2% 14% 47% Autoimmune Ischemia 4% Wilson Other Indeterminate 5% 3% 7% 11% Hepatitis Etiology of Acute Liver Failure in 3-18y olds Acetaminophen Autoimmune Metabolic Drugs 46% 18% 8% Viral Ischemia Other 7% 7% 6% 4%4% Indeterminate Hepatitis *Acute Liver Failure (US)/ Hepatology 2008;47:1401

Trends in the incidence of hepatitis A virus related acute liver failure in the United States. The incidence of patients undergoing liver transplantation for HAV related ALF in the UNOS database significantly declined between 1988 and 2005 (P<.001) Similarly, the frequency of HAV patients enrolled in the ALFSG significantly declined between 1998 and 2005 ( P=.007). *Taylor RM et al. Hepatology 2006;44:1589

Outcomes of patients with HAV listed for liver transplantation in the UNOS database. All patients were listed between 1/98 and 9/15/05 *Taylor RM et al. Hepatology 2006;44:1589

Outcomes of patients with HAV enrolled in the Acute Liver Failure e Study Group* All patients were enrolled between 1/98 and 9/15/05.and followed for 3 weeks after enrollment *Taylor RM et al. Hepatology 2006;44:1589

Outcomes of patients with HAV enrolled in the Acute Liver Failure Study Group* All patients were enrolled between 1/98 and 9/15/05 and followed for 3 weeks after enrollment Results 16 HAV patients recovered spontaneously (55%) 13 HAV patients were transplanted or died (45%)

Factors with an impact on fatality rate in fulminant hepatitis A Host Age co-infection with hepatotrophic viruses immune response? Virus genomic variations virulence Treatment for liver failure improved intensive care liver transplantation

Risk factors associated with fulminant hepatitis A and liver failure Age of infection Chronic liver disease and co-infection with other hepatotrophic viruses (HBV, HCV) Intake of paracetamol Viral factors? Pregnancy???

Increased severity of HAV infection In the elderly: hospitalization rates rose from 3% in 40-49y olds to 42% <age of 70y (Brown&Persley Southern Med J 2002;95:826) In HCV, HBV and HIV co-infection (Laurence JC Am J Med 2005;118:75) In pregnancy (Elinav E et al.* Gastroenterology 2006;130:1129, Gall A Am J Med 2005;118:96S) *34/79458 acute hepatitis 13/34 Acute HAV 'with premature contractions, placenta separation, membrane rupture

Fulminant hepatitis associated with hepatitis A virus super-infection in patients with chronic hepatitis C In a prospective study, 27/595 adults with chronic liver disease (HBV,n=163) and chronic HCV,n=432) developed acute hepatitis A 17/27 patients who developed acute HAV had chronic HCV infection 7/10 patients with chronic HCV developed fulminant hepatitis A Vs 0/10 HBV patients Vento S et al. NEJM 1998;338:286

Increased incidence of fulminant hepatitis A in previuosly unrecognized HBsAg carriers with acute hepatitis* Incidene of liver failure - 3.2% in patients hospitalized for acute hepatitis, irrespective of etiology (5/157) Incidence of liver failure in HBsAg+ subjects 20.3% (36/177);P<0.001 Conclusion: HBsAg carriers were at 9 Fold increased risk of fulminant hepatitis A than non-cariers *Chu CM, Liaw YF. Infection 2005;33:136

Search for host and viral factors associated with an increased risk for developement of fulminant hepatitis A In spite of the unique single HAV serotype, some genetic diversity has been evident from the sequencing data obtained from a large number of HAV isolates Based on sequence variations at the VP1/2A junction, genotypes and subgenotypes have been defined So far - no confirmed correlation was found between defined HAV sequences and increased risk for developing fulminant hepatitis A. However the issue remains open.

Viral Risk factors associated with fulminant HAV* 19/76 subjects with acute ALF and encephalopathy were significantly older, had higher bilirubin levels, and were more likely to be females.(older age was not confirmed by multivariate analysis) 40/76 patients reported intake of medications of whom 19 took acetaminophen (<3.0gr/day) for less than 3 days 36/50 patients with available serum were HAV-RNA positive (>100 copies/ml) Phylogenetic analysis revealed 18 patients with genotype 1A, 12 patients 1B and 4 patients with genotype 3 9/19 patients with fulminant hepatitis A and encephalopathy had undetectable HAV-RNA (VP1/2A PCR), compared to 5/31 controls without ALF (P<.02) 8/19 patients recovered spontaneously and 10 were transplanted High bilirubin levels and low viremia were significantly related to risk of death or transplantation by mutivariate analysis *Rezende G et al. Hepatology 2003;38:613

Selected day 1 clinical features of patients with FH - ALFSG* Spontaneous survival Transplanted /Died P Age 44 54 NS Female (%) 69 23.008 MELD score 29 34 NS ALT (u) at admis..03 3362 1675.03 Alk. Phosphat. 179 118.02 Creatinine >2md/dl 13% 54% NS Grade 3-4 encephalopathy 38% 69% NS Pressors 0% 46%.0004 Intubation 25% 85%.01 *Taylor RM et al. Hepatology 2006;44:1589

Models to Predict Transplant/Death in 29 Patients With Hepatitis A Enrolled in the Acute Liver Failure Study Group Model n Sensitivity Specificity PPV NPV AURO ALFSG index * >1 Factor 20 100% 56% 65% 100%.781 >2 Factors 14 92% 88% 86% 93%.899 >3 Factors 9 62% 94% 89% 75%.766 4 Factors 1 8% 100% 100% 57%.538 Other models MELD >35 9 54% 88% 78% 70%.707 King's College 5 31% 94% 80% 62%.623 *Taylor RM et al. Hepatology 2006;44:1589

Phylogenetic analysis of HAV in sera of Japanese patients with fulminant hepatitis Association between severity of hepatitis and genomic variations Mutations at the 5 NCR corresponding to the internal ribosome entry site may increase severity of liver disease in HAV (N=27 patients) Full length genome study in 3 patients suggests that these changes are not related to genotype Similar changes were also found in HAV adopted for growth in tissue culture Investigators conclusion: Genetic organization of HAV may influence replication and virulence Fujiwara K. et al. Dig Dis Sci 2000;45:2422 Fujiwara K et al. J Hepatol 200135:112 Fujiwara K et al. Liver Int 2005;25:194 Fujiwara K et al. Liver Int 2008, Epub

Molecular characterization of HAV in children with fulminant hepatic failure in Argentina: 9/2003-1/2006* N=41 children, age M 6.8y (1-15y),22F/19M HAV-RNA analyzed through probes of the 5 non-coding and VP1/2A regions 18/41 HAV cases positive for the 5 NCR (39%) and 18/41 HAV cases for the VP1/2A region (39%) FHF variants had some minor differences in nucleotide or amino acid sequences as compared to self limited acute HAV cases with no common pattern of substitution, temporal and geographic parameters *Munne MS et al.liver Int 2008

Putative Host Factors (Familial Clustering)* 3 siblings developed fulminant hepatitis A in a family in Israel Cloning and sequencing of HAV in progress *Durst RY et al. J Clin Gastroenterol. 2001;32:453

Conclusions The incidence of fulminant hepatitis A is low but there seems to be an increase in reports in children Improved intensive care and liver transplantation have markedly changed the fatality rates from fulminant hepatitis A Major risk factors include age, underlying liver disease and intake of paracetamol Conflicting and yet unconfirmed data have been reported on minor genetic substitutions of viral sequences with a putative impact on viral replication and cytopathic effect

Thank You The Hadassah-Hebrew University Campus Jerusalem, Israel